Targeting PMN‐MDSCs via CD300ld receptor for cancer immunotherapy
Open Access
- 11 January 2024
- journal article
- editorial
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (1) , e1534
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (82341025, 32270137, 82272142)
This publication has 18 references indexed in Scilit:
- Tumour-associated neutrophils in patients with cancerNature Reviews Clinical Oncology, 2019
- Targeting cancer-associated neutrophilsNature Reviews Drug Discovery, 2019
- Fatty acid transport protein 2 reprograms neutrophils in cancerNature, 2019
- Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in miceScience, 2018
- Molecular and Biochemical Aspects of the PD-1 Checkpoint PathwayNew England Journal of Medicine, 2016
- The role of myeloid cells in cancer therapiesNature Reviews Cancer, 2016
- Occurrence and significance of tumor‐associated neutrophils in patients with colorectal cancerInternational Journal of Cancer, 2016
- The prognostic landscape of genes and infiltrating immune cells across human cancersNature Medicine, 2015
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2014
- ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosisJournal of Clinical Investigation, 2014